首页> 外文期刊>Open Journal of Nephrology >An Evaluation of the Benefit of Cytomegalovirus Prophylaxis with Acyclovir on Post-Transplant Cytomegalovirus Infection Prevention in a Population of Renal Transplant Recipients in Nigeria
【24h】

An Evaluation of the Benefit of Cytomegalovirus Prophylaxis with Acyclovir on Post-Transplant Cytomegalovirus Infection Prevention in a Population of Renal Transplant Recipients in Nigeria

机译:评价患有ACYCLOVIR对尼日利亚肾移植受者患者后移植后胞嘧啶病毒感染预防的患有ACYCLOVIR的益处

获取原文
       

摘要

Background: Cytomegalovirus (CMV) is an important infection in renal transplant recipients and may significantly impact recipients’ long-term outcome and graft survival. Objective: This study aimed to evaluate the benefit of prophylaxis with acyclovir on post-transplant CMV infection prevention in a population of renal transplant recipients in Lagos, Nigeria. Subjects and Methods: The study was a cross-sectional design involving renal transplant recipients attending post-transplant follow-up clinics in Lagos, Nigeria between October 2004 and July 2005. Data on the use of CMV prophylaxis were obtained from the hospital case records of the study subjects. Enzyme-Linked Immunosorbent Assay (ELISA) was employed to detect CMV IgM antibodies for the diagnosis of post-transplant CMV infection and Microsoft Excel and EPI-Info 2002 statistical software were used for data entry and analysis. Results: Forty (40) renal transplant recipients were studied, 32 recipients were males and 8 were females with M:F ratio of 4:1. The mean age of the recipients was 39 ± 11.6 years old. The recipients’ post-transplant duration ranged from 2 to 80 months (Mean 17.6 ± 18.6 months). Fifteen (37.5%) of the transplant recipients received acyclovir prophylaxis for six months, one recipient (2.5%) received ganciclovir prophylaxis for three weeks while 24 recipients (60%) received no prophylactic therapy. There was no significant difference in the prevalence of seropositive CMV-IgM between transplant recipients who used CMV prophylaxis and those who did not (Fisher exact p = 0.45). Conclusion: Prophylaxis with acyclovir for six months showed no significant benefit on post-transplant CMV infection prevention in renal transplant recipients.
机译:背景:Cytomegalovirus(CMV)是肾移植受者的重要感染,可显着影响受体的长期结果和移植物存活。目的:本研究旨在评估尼日罗斯肾移植受者肾移植受者中移植后CMV感染预防的预防患者。主题和方法:该研究是涉及2004年10月至2005年10月之间的尼日利亚纳伯福斯后移植后续诊所的肾移植受试者的横截面设计。关于使用CMV预防的数据是从医院案例记录中获得的研究科目。使用酶联免疫吸附测定(ELISA)检测CMV IgM抗体用于诊断移植后CMV感染,Microsoft Excel和EPI-Info 2002统计软件用于数据进入和分析。结果:研究了四十(40)名肾移植受体,32名受者是男性,8例是M:F比为4:1的女性。接受者的平均年龄为39±11.6岁。接受者的移植后持续时间为2至80个月(平均17.6±18.6个月)。十五(37.5%)移植受者接受了六个月的Acyclovir预防,一个受体(2.5%)收到了三周,而24名受试者(60%)没有预防治疗,接受了三周的受体(2.5%)。使用CMV预防的移植接受者与没有(FISHER精确P = 0.45)的移植接受者之间的血清阳性CMV-IGM患病率没有显着差异。结论:六个月的Acyclovir预防对移植后的CMV感染预防没有显着效益肾移植受者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号